NM_002878.4(RAD51D):c.404T>C (p.Val135Ala) AND Breast-ovarian cancer, familial, susceptibility to, 4

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Jul 30, 2022
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV002593737.3

Allele description [Variation Report for NM_002878.4(RAD51D):c.404T>C (p.Val135Ala)]

NM_002878.4(RAD51D):c.404T>C (p.Val135Ala)

Genes:

RAD51D:RAD51 paralog D [Gene - OMIM - HGNC]
RAD51L3-RFFL:RAD51L3-RFFL readthrough [Gene]

Variant type:

single nucleotide variant

Cytogenetic location:

17q12

Genomic location:

Preferred name:

NM_002878.4(RAD51D):c.404T>C (p.Val135Ala)

HGVS:

NC_000017.11:g.35107064A>G
NG_031858.1:g.17806T>C
NM_001142571.2:c.464T>C
NM_002878.4:c.404T>CMANE SELECT
NM_133629.3:c.145-583T>C
NP_001136043.1:p.Val155Ala
NP_002869.3:p.Val135Ala
NP_002869.3:p.Val135Ala
LRG_516t1:c.404T>C
LRG_516:g.17806T>C
LRG_516p1:p.Val135Ala
NC_000017.10:g.33434083A>G
NM_002878.3:c.404T>C
NR_037711.2:n.430T>C

Protein change:

V135A

Molecular consequence:

NM_133629.3:c.145-583T>C - intron variant - [Sequence Ontology: SO:0001627]
NM_001142571.2:c.464T>C - missense variant - [Sequence Ontology: SO:0001583]
NM_002878.4:c.404T>C - missense variant - [Sequence Ontology: SO:0001583]
NR_037711.2:n.430T>C - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Name:: Breast-ovarian cancer, familial, susceptibility to, 4
Synonyms:: Breast-ovarian cancer, familial 4
Identifiers:: MONDO: MONDO:0013669; MedGen: C3280345; Orphanet: 145; OMIM: 614291

Recent activity

Clear Turn Off Turn On

Mus musculus cytosolic iron-sulfur assembly component 2A (Ciao2a), transcript va...
Mus musculus cytosolic iron-sulfur assembly component 2A (Ciao2a), transcript variant 1, mRNA
gi|71773979|ref|NM_026635.3|

Nucleotide
Mus musculus clone 220n14 Naip2 gene, partial sequence
Mus musculus clone 220n14 Naip2 gene, partial sequence
gi|8895967|gb|AF240494.1|AF240494

Nucleotide
Marchantia polymorpha strain Tak-1 unplaced genomic scaffold scaffold_92, whole ...
Marchantia polymorpha strain Tak-1 unplaced genomic scaffold scaffold_92, whole genome shotgun sequence
gi|1376842378|gb|KZ772764.1||gnl|WG G01|scaffold_92

Nucleotide
P20 protein, partial [Bamboo mosaic virus satellite RNA]
P20 protein, partial [Bamboo mosaic virus satellite RNA]
gi|757819616|gb|AJO26616.1|

Protein
uncultured bacterium nitrogenase reductase (nifH) gene, partial cds.
uncultured bacterium nitrogenase reductase (nifH) gene, partial cds.
PopSet: 459652960

PopSet

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV002939573	Labcorp Genetics (formerly Invitae), Labcorp	criteria provided, single submitter (Invitae Variant Classification Sherloc (09022015))	Uncertain significance (Jul 30, 2022)	germline	clinical testing	PubMed (1) [See all records that cite this PMID]

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV002939573

Labcorp Genetics (formerly Invitae), Labcorp

criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))

Uncertain significance
(Jul 30, 2022)

germline

clinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]

PMID:: 28492532
PMCID:: PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV002939573.2

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	PubMed (1)

Description

Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant has not been reported in the literature in individuals affected with RAD51D-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.003%). This sequence change replaces valine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 135 of the RAD51D protein (p.Val135Ala).

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Sep 29, 2024

ClinVar

Relating variation to medicine